デフォルト表紙
市場調査レポート
商品コード
1439956

非侵襲的出生前検査の世界市場:洞察、競合情勢、市場予測:2030年

Non invasive Prenatal Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
非侵襲的出生前検査の世界市場:洞察、競合情勢、市場予測:2030年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非侵襲的出生前検査の市場規模は、2023年に39億1,600万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に9.22%のCAGRで拡大し、2030年には66億4,500万米ドルに達すると予測されています。非侵襲的出生前検査の需要は、主に妊娠後期の急増と、ダウン症候群、エドワーズ症候群、脆弱X症候群、クラインフェルター症候群、トリプルX症候群、ターナー症候群などの染色体疾患の有病率の上昇によって後押しされています。さらに、非侵襲的出生前検査に対する償還計画の改善、ハイリスク妊娠のために高度な遺伝子検査を選択する医師の増加、妊娠を遅らせたいという願望、妊娠第3期または第2期における妊娠関連の問題の増加、機器の技術革新などが、2024年から2030年までの予測期間中の非侵襲的出生前検査市場の全体的な成長に寄与しています。

国際機関である国連は、最新のデータにおいて、ダウン症の推定発生率は全世界の出生数1,000~1,100人に1人であると発表しました。毎年、世界中で約3,000人から5,000人の子供がこの染色体異常で生まれています。

さらに、世界保健機関(WHO)2023年版は、先天性障害が原因で、毎年世界中で約24万人の新生児が生後28日以内に死亡していると明記しました。先天性疾患により、生後1カ月から5歳までの間にさらに17万人の子供が死亡しています。また、重篤な先天性障害を持って生まれた子どもの10人中9人は、低・中所得国で生まれています。

非侵襲的出生前検査の一種である超音波検査は、妊娠初期にはダウン症や主要な構造異常のスクリーニングに、妊娠後期には重度の胎児異常のスクリーニングに使用できます。NIPTのもう一つのタイプである母体血は、染色体異常や神経管欠損のリスク予測に役立つ胎盤マーカーのスクリーニングや、多くの染色体異常をスクリーニングするための遊離胎児DNAに使用することができます。絨毛膜絨毛サンプリングや羊水穿刺などの診断検査は、リスクの高い女性の染色体異常や感染症の診断に用いることができます。

当レポートでは、世界の非侵襲的出生前検査市場について調査し、市場の概要とともに、製品タイプ別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 非侵襲的出生前検査市場レポートのイントロダクション

第2章 非侵襲的出生前検査市場のエグゼクティブサマリー

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 非侵襲的出生前検査市場の主な要因分析

  • 非侵襲的出生前検査市場の促進要因
  • 非侵襲的出生前検査市場の抑制要因と課題
  • 非侵襲的出生前検査市場の機会

第5章 非侵襲的出生前検査市場におけるポーターのファイブフォース分析

第6章 非侵襲的出生前検査市場に対するCOVID-19の影響分析

第7章 非侵襲的出生前検査市場の概要

  • 製品タイプ別
  • 適応症別
  • エンドユーザー別
  • 地域別

第8章 非侵襲的出生前検査市場の企業と製品プロファイル

  • PerkinElmer Inc.
  • Natera, Inc.
  • Invitae Corporation
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd
  • Quest Diagnostics Incorporated
  • MedGenome Labs Ltd
  • Ravgen
  • Eurofins Scientific
  • BGI
  • Illumina, Inc.
  • MedGenome Labs Ltd
  • YOURGENE HEALTH
  • Qiagen
  • Agilent Technologies, Inc.

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Non-Invasive Prenatal Testing Market in Global (2021-2030)
  • Table 4: Non-Invasive Prenatal Testing Market in Global by Product Type (2021-2030)
  • Table 5: Non-Invasive Prenatal Testing Market in Global by Indication (2021-2030)
  • Table 6: Non-Invasive Prenatal Testing Market in Global by End-User (2021-2030)
  • Table 7: Non-Invasive Prenatal Testing Market in Global by Geography (2021-2030)
  • Table 8: Non-Invasive Prenatal Testing Market in North America (2021-2030)
  • Table 9: Non-Invasive Prenatal Testing Market in North America by Country (2021-2030)
  • Table 10: Non-Invasive Prenatal Testing Market in the US (2021-2030)
  • Table 11: Non-Invasive Prenatal Testing Market in Canada (2021-2030)
  • Table 12: Non-Invasive Prenatal Testing Market in Mexico (2021-2030)
  • Table 13: Non-Invasive Prenatal Testing Market in Europe (2021-2030)
  • Table 14: Non-Invasive Prenatal Testing Market in Europe by Country (2021-2030)
  • Table 15: Non-Invasive Prenatal Testing Market in France (2021-2030)
  • Table 16: Non-Invasive Prenatal Testing Market in Germany (2021-2030)
  • Table 17: Non-Invasive Prenatal Testing Market in the United Kingdom (2021-2030)
  • Table 18: Non-Invasive Prenatal Testing Market in Italy (2021-2030)
  • Table 19: Non-Invasive Prenatal Testing Market in Spain (2021-2030)
  • Table 20: Non-Invasive Prenatal Testing Market in the Rest of Europe (2021-2030)
  • Table 21: Non-Invasive Prenatal Testing Market in Asia-Pacific (2021-2030)
  • Table 22: Non-Invasive Prenatal Testing Market in Asia-Pacific by Country (2021-2030)
  • Table 23: Non-Invasive Prenatal Testing Market in China (2021-2030)
  • Table 24: Non-Invasive Prenatal Testing Market in Japan (2021-2030)
  • Table 25: Non-Invasive Prenatal Testing Market in India (2021-2030)
  • Table 26: Non-Invasive Prenatal Testing Market in Australia (2021-2030)
  • Table 27: Non-Invasive Prenatal Testing Market in South Korea (2021-2030)
  • Table 28: Non-Invasive Prenatal Testing Market in Rest of Asia-Pacific (2021-2030)
  • Table 29: Non-Invasive Prenatal Testing Market in the Rest of the World (2021-2030)
  • Table 30: Non-Invasive Prenatal Testing Market in RoW by Region (2021-2030)
  • Table 31: Non-Invasive Prenatal Testing Market in the Middle East (2021-2030)
  • Table 32: Non-Invasive Prenatal Testing Market in Africa (2021-2030)
  • Table 33: Non-Invasive Prenatal Testing Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Non-Invasive Prenatal Testing Market in Global (2021-2030)
  • Figure 4: Non-Invasive Prenatal Testing Market in Global by Product Type (2021-2030)
  • Figure 5: Non-Invasive Prenatal Testing Market in Global by Indication (2021-2030)
  • Figure 6: Non-Invasive Prenatal Testing Market in Global by End-User (2021-2030)
  • Figure 7: Non-Invasive Prenatal Testing Market in Global by Geography (2021-2030)
  • Figure 8: Non-Invasive Prenatal Testing Market in North America (2021-2030)
  • Figure 9: Non-Invasive Prenatal Testing Market in North America by Country (2021-2030)
  • Figure 10: Non-Invasive Prenatal Testing Market in the US (2021-2030)
  • Figure 11: Non-Invasive Prenatal Testing Market in Canada (2021-2030)
  • Figure 12: Non-Invasive Prenatal Testing Market in Mexico (2021-2030)
  • Figure 13: Non-Invasive Prenatal Testing Market in Europe (2021-2030)
  • Figure 14: Non-Invasive Prenatal Testing Market in Europe by Country (2021-2030)
  • Figure 15: Non-Invasive Prenatal Testing Market in France (2021-2030)
  • Figure 16: Non-Invasive Prenatal Testing Market in Germany (2021-2030)
  • Figure 17: Non-Invasive Prenatal Testing Market in the United Kingdom (2021-2030)
  • Figure 18: Non-Invasive Prenatal Testing Market in Italy (2021-2030)
  • Figure 19: Non-Invasive Prenatal Testing Market in Spain (2021-2030)
  • Figure 20: Non-Invasive Prenatal Testing Market in the Rest of Europe (2021-2030)
  • Figure 21: Non-Invasive Prenatal Testing Market in Asia-Pacific (2021-2030)
  • Figure 22: Non-Invasive Prenatal Testing Market in Asia-Pacific by Country (2021-2030)
  • Figure 23: Non-Invasive Prenatal Testing Market in China (2021-2030)
  • Figure 24: Non-Invasive Prenatal Testing Market in Japan (2021-2030)
  • Figure 25: Non-Invasive Prenatal Testing Market in India (2021-2030)
  • Figure 26: Non-Invasive Prenatal Testing Market in Australia (2021-2030)
  • Figure 27: Non-Invasive Prenatal Testing Market in South Korea (2021-2030)
  • Figure 28: Non-Invasive Prenatal Testing Market in Rest of Asia-Pacific (2021-2030)
  • Figure 29: Non-Invasive Prenatal Testing Market in the Rest of the World (2021-2030)
  • Figure 30: Non-Invasive Prenatal Testing Market in RoW by Region (2021-2030)
  • Figure 31: Non-Invasive Prenatal Testing Market in the Middle East (2021-2030)
  • Figure 32: Non-Invasive Prenatal Testing Market in Africa (2021-2030)
  • Figure 33: Non-Invasive Prenatal Testing Market in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Marker Opportunities
  • Figure 37: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0637

Non-Invasive Prenatal Testing Market By Product Type (Instruments And Kits And Reagents), By Indication (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, And Others), By End-User (Hospitals, Diagnostic Labs, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of chromosomal disorders and the increasing demand for early and non-invasive fetal diagnosis across the globe

The global non-invasive prenatal testing market was valued at USD 3,916 million in 2023, growing at a CAGR of 9.22% during the forecast period from 2024 to 2030 to reach USD 6,645 million by 2030. The demand for non-invasive prenatal testing is primarily being boosted by the surging late pregnancy numbers and rising prevalence of chromosomal disorders such as down syndrome, Edwards syndrome, fragile X syndrome, Klinefelter syndrome, triple-X syndrome, turner syndrome, and others. Further, improving reimbursement plans for noninvasive prenatal tests, an increasing number of doctors choosing advanced genetic testing for high-risk pregnancies, a desire to delay pregnancy, more pregnancy-related problems in the third- or second trimester, and innovation in devices among others are thereby contributing to the overall growth of the non-invasive prenatal testing market during the forecast period from 2024-2030.

Non-Invasive Prenatal Testing Market Dynamics:

The United Nations, an international organization, in the latest data provided that the estimated incidence of Down syndrome is between 1 in 1,000 to 1 in 1,100 live births worldwide. Each year, approximately 3,000 to 5,000 children are born with this chromosome disorder, across the globe.

The Down's Syndrome Association stated that around one in every 1000 babies born in the United Kingdom has Down's syndrome. In 2022, there were approximately 47,000 people in the UK with the condition.

Further, the World Health Organization (WHO) 2023, specified that approximately 240,000 newborns die worldwide within 28 days of birth every year due to congenital disorders. Congenital disorders cause a further 170,000 deaths of children between the ages of 1 month and 5 years. Also, nine of ten children born with a serious congenital disorder are in low- and middle-income countries.

Ultrasound, a type of non-invasive prenatal testing can be used to screen for down syndrome and major structural abnormalities during the first trimester, and for severe fetal anomalies during the second trimester. Maternal blood, another type of NIPT can be used for screening the placental markers to aid in the prediction of risk of chromosomal abnormalities or neural tube defects, or for free fetal DNA to screen for many chromosomal abnormalities. Diagnostic tests such as chorionic villus sampling and amniocentesis can be used to diagnose chromosomal abnormalities and infections in women at high risk.

Thus, the increasing figures of down syndrome and other chromosomal abnormalities will increase the demand for various non-invasive prenatal testing kits and instruments, thereby propelling the overall market.

Additionally, the advantages of non-invasive prenatal tests over other prenatal tests, such as the non-invasive nature of tests, better accuracy, and short duration of the procedure, are anticipated to hasten the growth of the NIPT market during the forecast period. Furthermore, awareness programs by public organizations are another factor propelling the market growth.

With existing key players operating in the NIPT market, the market is highly saturated. So the companies are forming partnerships and collaborations to maintain a stable market position. For instance, in May 2022, Illumina, a global leader in DNA sequencing and array-based technologies, and Next Generation Genomic, the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, did a partnership to launch VeriSeq(TM) NIPT solution in Thailand.

Therefore, the above-mentioned factors are contributing to the growth of the non-invasive prenatal testing market during the forecast period from 2024-2030.

However, stringent regulations and ethical concerns, a high rate of false positive results, and others may restrict the non-invasive prenatal testing market growth.

The non-invasive prenatal testing market experienced significant growth during the COVID-19 pandemic. In the initial period, the market suffered a temporary setback as lockdown restrictions were enforced as a necessary step to curb the spread of COVID-19. However, the demand for non-invasive prenatal testing kits and instruments increased during the pandemic owing to the sudden increase in the number of pregnancy cases. According to UNICEF 2020, globally, an estimated 116 million babies were born under the shadow of the COVID-19 pandemic, and almost a quarter of them which is approximately 29 million were born in South Asia. Countries in South Asia with the expected highest numbers of births in the nine months since the COVID-19 pandemic declaration were India (20 million), Pakistan (5 million), Bangladesh (2.4 million), and Afghanistan (1 million). The increasing number of pregnancy cases increased the demand for non-invasive prenatal testing, due to which various key players in the market accelerated the manufacturing of NIPT kits, reagents, and instruments. Henceforth, the afore-said factors propelled the demand for non-invasive prenatal testing during the pandemic and are estimated to grow similarly during the forecast period.

Non-Invasive Prenatal Testing Market Segment Analysis:

Non-Invasive Prenatal Testing Market By Product Type (Instruments and Kits and Reagents), Indication (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the non-invasive prenatal testing market, the kits and reagents category is expected to amass significant revenue share in the year 2023. This can be ascribed to the presence of major players offering a wide range of consumables, kits, and reagents for NIPT.

The non-invasive prenatal test kits are innovative genetic screening procedures for pregnant women who are at risk of fetal Patau syndrome, Edward's Syndrome, or Down syndrome. These rapid, reliable, and safe kits quickly and effectively detect trisomy 13, 18, and 21, and can be carried out by the healthcare provider.

These kits can be prescribed early stage of pregnancy, after only 10 weeks of pregnancy. The results of the blood test available in around 7 working days. These kits are efficient, safe, and remarkably accurate. The kits have been found to reduce unnecessary invasive sampling by up to 95%.

Further, the CE-marked Harmony IVD Kit offered by Roche is an extensively studied and validated NIPT test and has been employed to screen more than 1.8 million pregnancies. The Harmony test is highly efficient and offers less than a 0.1% false-positive rate for trisomies 13, 18, and 21.

Also, the Vanadis Core T21/T18/T13 Reagent Cartridge, by PerkinElmer, is a qualitative assay intended for an in vitro diagnostic in screening for the risk of trisomy 21, 18, and/or 13 in fetus using cell-free DNA from pregnant women of at least 10 weeks of gestation.

Therefore, owing to the above factors, the demand for kits and reagents is predicted to increase thereby driving the growth of the overall non-invasive prenatal testing market during the forecast period.

North America is expected to dominate the overall Non-Invasive Prenatal Testing Market:

Among all the regions, North America is estimated to account for the largest share of the non-invasive prenatal testing market in the year 2023. Factors such as the high preterm birth rate, high maternal mortality rate, and rising incidences of chromosomal abnormalities such as down syndrome, among others will create a positive impact on the North American non-invasive prenatal testing market. Furthermore, sophisticated healthcare infrastructure, regulatory approval for new products, high diagnosis rates, wider adoption and awareness among the people, and the introduction of new and technologically advanced tests also helped the market growth in this region.

Further, the United States holds the major share in North America and the globally non-invasive prenatal testing market, one of the key reasons includes the rising number of down syndrome in the United States population. As per the Centers for Disease Control and Prevention (CDC) 2022, each year, about 6,000 babies born in the United States have Down syndrome. This means that Down syndrome occurs in about 1 in every 700 babies, in the US.

Furthermore, high diagnosis rates, increased adoption and awareness, and the introduction of new and technologically advanced tests are all contributing to market growth in North America. In addition to the current IONA test, which offers to screen for trisomies 21, 18, and 13, Yourgene launched IONA Care in the US, in May 2022. IONA care is a non-invasive prenatal test (NIPT) service offering to measure whether a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA) and autosomal aneuploidies (AA). As a result, such product launches are expected to boost market growth during the forecast period.

Moreover, the strong geographical foothold of players in the US offering advanced tests has been pivotal in the growing adoption of these tests in the US. For instance, the Panorama test, developed by Natera, analyses DNA using single-nucleotide polymorphism (SNP) technology and is the only test that can distinguish between maternal and fetal DNA in the chromosomes of interest. Such innovative developments are likely to accelerate the adoption of NITP and thereby drive the North America non-invasive prenatal testing market forward during the forecast period.

Non-Invasive Prenatal Testing Market Key Players:

Some of the key market players operating in the non-invasive prenatal testing market include PerkinElmer Inc., Natera, Inc., Invitae Corporation, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, MedGenome Labs Ltd, Ravgen, Eurofins Scientific, BGI, Illumina, Inc., MedGenome Labs Ltd., YOURGENE HEALTH, Qiagen, Agilent Technologies, Inc., and others.

Recent Developmental Activities in the Non-Invasive Prenatal Testing Market:

In August 2022, Natera Inc. filed a pre-submission to the Food and Drug Administration (FDA) for its panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.

In July 2022, Genetic Technologies Limited acquired EasyDNA as the company expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe.

In March 2020, Yourgene Health acquired AGX-DPNI, its distribution partner for its Iona noninvasive prenatal test in France, for Euro 2.4 million ($2.7 million) in cash and up to Euro 1.7 million in cash earn-out payments based on sales growth performance.

In June 2019, June 2019, Illumina, Inc., announced the launch of VeriSeq(TM) NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu.

Key Takeaways from the Non-Invasive Prenatal Testing Market Report Study

Market size analysis for current non-invasive prenatal testing market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the non-invasive prenatal testing market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global non-invasive prenatal testing Market.

Various opportunities available for the other competitor in the non-invasive prenatal testing market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current non-invasive prenatal testing market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for non-invasive prenatal testing market growth in the coming future?

Target Audience who can be benefited from this Non-Invasive Prenatal Testing Market Report Study

Non-invasive prenatal testing products providers

Research organizations and consulting companies

Non-invasive prenatal testing-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in non-invasive prenatal testing

Various End-users who want to know more about the non-invasive prenatal testing market and the latest technological developments in the non-invasive prenatal testing market.

Frequently Asked Questions for the Non-Invasive Prenatal Testing Market:

1. What is non-invasive prenatal testing?

Non-invasive prenatal testing (NIPT), also called non-invasive prenatal screening (NIPS), is a method for determining the risk that the fetus will be born with certain genetic abnormalities. This testing analyses small DNA fragments circulating in a pregnant woman's blood. NIPT analyses the genetic information contained in this DNA to screen for several abnormalities.

2. What is the market for global non-invasive prenatal testing?

The global non-invasive prenatal testing market was valued at USD 3,916 million in 2023, growing at a CAGR of 9.22% during the forecast period from 2024 to 2030 to reach USD 6,645 million by 2030.

3. What are the drivers for the global non-invasive prenatal testing market?

The demand for non-invasive prenatal testing is primarily being heightened by the increasing number of babies with chromosomal disorders such as down syndrome, and Edwards syndrome owing to the increasing number of late pregnancies and increasing demand for early and non-invasive fetal diagnosis. In addition, the advantages of non-invasive prenatal testing over other prenatal tests such as their non-invasive nature, better accuracy, and short duration of the procedure, increasing product launches and approvals, and innovation in product development thereby contribute to the overall growth of the non-invasive prenatal testing market during the forecast period from 2024-2030.

4. Who are the key players operating in the global non-invasive prenatal testing market?

Some of the key market players operating in the non-invasive prenatal testing market include PerkinElmer Inc., Natera, Inc., Invitae Corporation, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, MedGenome Labs Ltd, Ravgen, Eurofins Scientific, BGI, Illumina, Inc., MedGenome Labs Ltd., YOURGENE HEALTH, Qiagen, Agilent Technologies, Inc., and others.

5. Which region has the highest share in the non-invasive prenatal testing market?

North America is expected to dominate the overall non-invasive prenatal testing market during the forecast period from 2024-2030. Factors such as the high preterm birth rate, high maternal mortality rate, and rising incidences of chromosomal abnormalities, among others will create a positive impact on the North American non-invasive prenatal testing market. Furthermore, sophisticated healthcare infrastructure, regulatory approval for new products, high diagnosis rates, wider adoption and awareness among the people, and the introduction of new and technologically advanced tests also helped the market growth in this region.

Table of Contents

1. Non-Invasive Prenatal Testing Market Report Introduction

2. Non-Invasive Prenatal Testing Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Non-Invasive Prenatal Testing Market Key Factors Analysis

  • 4.1. Non-Invasive Prenatal Testing Market Drivers
    • 4.1.1. An increasing number of babies with chromosomal disorders owing to the increasing number of late pregnancies
    • 4.1.2. Increased demand for early and non-invasive fetal diagnosis
    • 4.1.3. Constant product innovations
  • 4.2. Non-Invasive Prenatal Testing Market Restraints and Challenges
    • 4.2.1. Stringent regulations and ethical concerns
    • 4.2.2. High rate of false positive results
  • 4.3. Non-Invasive Prenatal Testing Market Opportunities
    • 4.3.1. Rising technological development to increase the accuracy of the device
    • 4.3.2. Growing insurance coverage for average and low-risk pregnancies

5. Non-Invasive Prenatal Testing Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Non-Invasive Prenatal Testing Market

7. Non-Invasive Prenatal Testing Market Layout

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Kits and Reagents
  • 7.2. By Indication
    • 7.2.1. Down Syndrome
    • 7.2.2. Edwards Syndrome
    • 7.2.3. Patau Syndrome
    • 7.2.4. Turner Syndrome
    • 7.2.5. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Labs
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.1.1. United States Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.1.2. Canada Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.1.3. Mexico Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
    • 7.4.2. Europe Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.1. France Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.2. Germany Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.4. Italy Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.5. Spain Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
    • 7.4.3. Asia-Pacific Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.1. China Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.2. Japan Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.3. India Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.4. Australia Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.5. South Korea Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia-Pacific Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW) Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.4.1. Middle East Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.4.2. Africa Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)
      • 7.4.4.3. South America Non-Invasive Prenatal Testing Market Size in USD million (2021-2030)

8. Non-Invasive Prenatal Testing Market Company and Product Profiles

  • 8.1. PerkinElmer Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Natera, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Invitae Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. CENTOGENE N.V.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. F. Hoffmann-La Roche Ltd
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Quest Diagnostics Incorporated
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. MedGenome Labs Ltd
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Ravgen
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Eurofins Scientific
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. BGI
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Illumina, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. MedGenome Labs Ltd
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. YOURGENE HEALTH
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Qiagen
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Agilent Technologies, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us